New opportunities for the prevention of gastric cancer

Maev I.G.; Kaziulin A.N.

doi:https://doi.org/10.17116/terarkh2017894101-109

Close metadata

Recommended articles:

Pancreaticoduodenectomy combined with multivisceral resections. Pirogov Russian Journal of Surgery. 2024;(11):77-83

The influence of Helicobacter pylori and duodenogastric reflux on the development and treatment outcomes of hyperplastic gastric polyps. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):5-9

Efficacy of alpha-glutamyl-tryptophan in the treatment of chronic atrophic gastritis: case series. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):121-128

Claudin-18.2 and gastric cancer: from physiology to carcinogenesis. Russian Journal of Archive of Pathology. 2024;(6):92-99

Experience of successful treatment of leaks of high esophageal-intestinal anastomoses after gastrectomy by means of video-assisted thoracoscopic debridement and cycles of vacuum active aspiration system. P.A. Herzen Journal of Oncology. 2024;(6):63-69

Gastric cancer: incidence, risk factors, screening. Russian Journal of Preventive Medicine. 2024;(12):135-139

Evaluating the efficacy of the Kyoto classification of gastritis in diagnosing Helicobacter pylori infection. Russian Journal of Evidence-Based Gastroenterology. 2025;(1):29-38

The phenomenon of tumor budding in gastric cancer. Russian Journal of Archive of Pathology. 2025;(2):79-87

Study of serum cytokine concentration in primary patients with gastric cancer. P.A. Herzen Journal of Oncology. 2025;(2):25-29

Total gastrectomy with preserving duodenal passage by double tract reconstruction in patients with gastric cancer. Pirogov Russian Journal of Surgery. 2025;(6):35-43

Abstract:

The approvals and provisions of the Management of Helicobacter pylori infection-the Maastricht V/ Florence Consensus Report and those of the Kyoto Global Consensus Conference on H. pylori-associated gastritis, concerning with the primary and secondary prevention of gastric cancer (GC), unambiguously suggest that H. pylori infection is the most important risk factor of GC. Accordingly, the basis for the primary and secondary prevention of GC is the optimization of H. pylori eradication therapy. The clear direct relationship of the risk of GC to the severity and extent of atrophic gastritis, intestinal metaplasia and dysplasia and no reversal of intestinal metaplasia and dysplasia in the presence of H. pylori eradication presume that gastroprotective agents should be used for primary and secondary prevention. Experimental and clinical findings can lead to the conclusion that rebamipide is a highly effective and safe agent for the primary and secondary prevention of GC in patients with and without H. pylori infection, by optimizing anti-Helicobacter therapy, its anti-inflammatory effect and ability to restore the cellular structure of the gastric epithelium.

Keywords:

gastric cancer

cancer prevention

Helicobacter pylori

rebamipide

Authors:

Maev I.G.

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia

Kaziulin A.N.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet im. A.I. Evdokimova Minzdrava RF

Close metadata

References:

Malignant tumors in Russia in 2009 (morbidity and mortality). Ed. Chissova VI, Starinskaya VV, Petrova GM. 2011. (In Russ.)
Abrams AJ, Wang TC. Adenocarcinoma and other tumors of the stomach. In: Feldman M, Friedman LS, Brandt LJ (eds): Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Management. 9th ed. Philadelphia:WB Saunders, 2010.
Maiev IV, Andreev DN. Gastric cancer: risk factors and opportunities of cancer prevention. Consilium Medicum. 2014;12:45-50. (In Russ.)
Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12 (3):354-362. doi:10.3748/wjg.v12.i3.354
Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J. 2005;81:419-424.
Chissov VI, Starinskiy VV, Petrova GV, eds. Malignant tumors in Russia in 2011 (morbidity and mortality). M.: P.A. Herzen Moscow Oncology Research Institute (MNIOI P.A. Gertsena) «Russian Ministry of Health». 2013;289. (In Russ.)
Maiev IV, Andreev DN et al. The evolution of ideas about the definition, classification, diagnosis and treatment of gastritis associated with infection by Helicobacter pylory. Farmateka. 2016;6:24-33. (In Russ.)
Han X, Jiang K, Wang B et al. Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study. Clin Drug Investig. 2015;35(10):665-673.
Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther. 1995;9(Suppl.2):45-51.
Pandey R, Misra V, Misra SP et al. Helicobacter pylori and gastric cancer. Asian Pac J Cancer Prev. 2010;11(3):583-588.
Barreto-Zuniga R, Maruyama M, Kato Y et al. Significance of Helicobacter pylori infection as a risk factor in gastric cancer: serological and histological studies. J Gastroenterol. 1997;32:289-294.
Miehlke S, Hackelsberger A, Meining A et al. Histological diagnosis of Helicobacter pylori gastritis is predictive of a high risk of gastric carcinoma. Int J Cancer. 1997;73:837-839.
Nomura AM, Stemmermann GN, Chyou PH. Gastric cancer among the Japanese in Hawaii. Jpn J Cancer Res. 1995;86:916-923.
Forman D, Newell DG, Fullerton F et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991;302:1302-1305.
Kamangar F, Qiao YL, Blaser MJ et al. Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China. Br J Cancer. 2007;96:172-176.
Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784-789.
de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607-615.
Zakharova NV, IG Bakulin, Simanenkov VI, Maslygina AA. Review of recommendations of the fifth Maastricht/Florence consensus on the diagnosis and treatment of infection of Helicobacter pylori. Farmateka. 2016;Gastroenterology/Hepatology:8-26. (In Russ.)
Correa P. Helicobacter pylori and gastric cancer: state of the art. Cancer Epidemiol Biomarkers Prev. 1996;5:477-481.
Sablin OA, Yurin M, Zakharova N, Simanenkov V. Efficiency of Eradication Therapy in Patients With Autoimmune Gastritis Associated With Helicobacter pylori: A Prospective Study Su1193. Gastroenterology. 2014;146(Suppl.1):S399.
Rokkas T, Pistiolas D, Sechopoulos P, et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter. 2007;12(Suppl.2):32-38.
Chen HN, Wang Z, Li X, et al. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016;19:166-175.
González CA, Megraud F, Buissonniere A, et al. Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project. Ann Oncol. 2012;23:1320-1324.
Ladeiras-Lopes R, Pereira AK, Nogueira A et al. Smoking and gastric cancer: Systematic review and meta-analysis of cohort studies. Cancer Causes Control. 2008;19:689-701.
Fuccio L, Zagari RM, Eusebi LH et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009;151:121-128.
Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection:a community-based study of gastric cancer prevention. Gut. 2013;62:676-682.
Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174.
Livzan MA, Kononov AV, Brain SI. The course of chronic gastritis associated with Helicobacter pylori in post-irridication period. The experimental and a wedge. Farmacol. 2007;5:116-123. (In Russ.)
Wang J, Xu L, Shi R et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion. 2011;83:253-260.
Shimizu N, Ikehara Y, Inada K et al. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Res. 2000;60:1512-1514.
Nozaki K, Shimizu N, Ikehara Y et al. Effect of early eradication on Helicobacter pylori-related gastric carcinogenesis in Mongolian gerbils. Cancer Sci. 2003;94:235-239.
Cai X, Carlson J, Stoicov C et al. Helicobacter felis eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice. Gastroenterology. 2005;128:1937-1952.
You WC, Brown LM, Zhang L et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006;98:974-983.
Take S, Mizuno M, Ishiki K, et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol. 2007;42(Suppl.7):21-27.
Oh S, Kim N, Yoon H, et al. Risk factors of atrophic gastritis and intestinal metaplasia in first-degree relatives of gastric cancer patients compared with age-sex matched controls. J Cancer Prev. 2013;18:149-160.
Openeko TG, Reshetnikov OV, Kurilovich SA, Simonova GI. Stomach cancer in Novosibirsk on the edge of Millennium (morbidity and mortality trends, prevention opportunities). Questions of Oncology. 2013;6:708-713. (In Russ.)
Leung WK, Ng EK, Chan WY et al. Risk factors associated with the development of intestinal metaplasia in first-degree relatives of gastric cancer patients. Cancer Epidemiol Biomarkers Prev. 2005;14:2982-2986.
Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353-1367.
Malfertheiner P, Sipponen P, Naumann M, et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol. 2005;100:2100-2115.
Malfertheiner P, Megraud F, O’Morain CA at al. The European Helicobacter Study Group (EHSG). Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut. 2012;61:646-664.
Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010;15:1-20.
Nordenstedt H, Graham DY, Kramer JR et al. Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol. 2013;108:65-71.
Correa P. Gastric cancer: overview. Gastroenterol Clin North Am. 2013;42:211-217.
Meining A, Bayerdörffer E, Müller P et al. Gastric carcinoma risk index in patients infected with Helicobacter pylori. Virchows Arch. 1998;432:311-314.
Naylor GM, Gotoda T, Dixon M et al. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut. 2006;55:1545-1552.
Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP) and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44:74-94.
de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134:945-952.
Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am. 2010;39:465-480.
Graham DY, Shiotani A. Which therapy for Helicobacter pylori infection? Gastroenterology. 2012;143:10-12.
Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12:177-186
Wu JY, Liou JM, Graham DY. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol. 2014;8:21-28.
Capelle LG, Haringsma J, de Vries AC, et al. Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy. Dig Dis Sci. 2010;55:3442-3448.
Osawa H, Yamamoto H, Miura Y, et al. Blue laser imaging provides excellent endsocopic images of upper gastrointestinal lesions. Video J Encyclopedia of GI endoscopy. 2014;1:607-610.
Pimentel-Nunes P, Dinis-Ribeiro M, Soares JB, et al. A multicenter validation of an endoscopic classification with narrow band imaging for gastric precancerous and cancerous lesions. Endsocopy. 2012;44:236-246.
Shiotani A, Cen P, Graham DY. Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol. 2013;23:492-501.
Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808-1825.
Graham DY, Fiscbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143-1153.
Maiev IV, Samsonov AA, Andreev DN, Kochetov SA, Andreev NG, Dichev DT. Modern aspects of diagnosis and treatment of infection Helicobacter pylori. Medical advice. 2012;8:10-19. (In Russ.)
Lazebnik LB, Masharova AA, Bordin DS, Khomeriki SG. Influence of Bismuth on Gastritis Healing and Effectiveness of Helicobacter pylori Eradication. Helicobacter. 2010;15:343.
Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther. 2011;34(11-12):1255-1268.
Yuan Y, Ford AC, Khan KJ. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;12:CD008337.
Yoon JH, Baik GH, Kim YS et al. Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication. Gut Liver. 2012;6(4):434-439.
Maiev IV, Samsonov AA, Korovin TI, et al. Bismuth tripotassium dicitratobismuthate increases the efficiency of first-line treatment of H. pylori. The experimental and a wedge. Gastroenterology. 2012;8:92-97. (In Russ.)
Maiev IV, Samsonov AA, Andreev DN. Diseases of the stomach. M.: GEOTAR Media; 2015. (In Russ.)
Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;7(347):f4587.
Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006;23(1):35-44.
Hayashi S, Sugiyama T, Amano K et al. Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob. Agents Chemother. 1998;42:1895-1899.
Genta RM. Review article: the role of rebamipide in the management of inflammatory disease of the gastrointestinal tract. Aliment Pharmacol Ther. 2003;18:8S-13S.
Du Y, Li Z, Zhan X et al. Anti-inflammatory Effects of Rebamipide According to Helicobacter pylori Status in Patients with Chronic Erosive Gastritis: A Randomized Sucralfate-Controlled Multicenter Trial in China-STARS Study. Dig Dis Sci. 2008;53:2886-2895.
Nishizawa T, Suzuki H, Nakagawa I et al. Rebamipide-promoted restoration of gastric mucosal sonic hedgehog expression after early Helicobacter pylori eradication. Digestion. 2009;79:259-262.
Nishizawa T, Nishizawa Y, Yahagi N et al. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: A systematic review and meta-analysis. Journal of Gastroenterology and Hepatology. 2014;29(Suppl.4):20-24.
Yoshida N, Yoshikawa T, Linuma S et al. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci. 1996;41(6):1139-1144.
Lee KH, Kim JY, Kim WK et al. Protective effect of rebamipide against Helicobacter pylori-CagA-induced effects on gastric epithelial cells. Dig Dis Sci. 2011;56(2):441-448.
Tarnawski AS, Chai J, Pai R, Chiou SK. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004;49:202-209.
Tanigawa T, Watanabe T, Ohkawa F et al. Rebamipide, a mucoprotective drug, inhibits NSAIDs-induced gastric mucosal injury: possible involvement of the downregulation of 15-hydroxyprostaglandin dehydrogenase. J Clin Biochem Nutr. 2011;48(2):149-153.
Kinjo N, Kawanaka H, Akahoshi T et al. Significance of ERK nitration in portal hypertensive gastropathy and its therapeutic implications. Am J Physiol Gastrointest Liver Physiol. 2008;295:1016-1024.
Nagano Y, Matsui H, Muramatsu M et al. Rebamipide significantly inhibits indomethacin-induced mitochondrial damage, lipid peroxidation, and apoptosis in gastric epithelial RGM-1 cells. Dig Dis Sci. 2005;50(Suppl.1):76-83.
Abe N, Funato H, Hirata A et al. Evaluation of Gastric Mucosal Injury Model Animals of Rebamipide Formulation-Study of Therapeutic Equivalence. Yakugaku Zasshi. 2016;136(4):677-684.
Koyama N, Sasabe H, Miyamoto G. Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Xenobiotica. 2002;32(7):573-586.
Hahm KB, Lee KJ, Kim YS et al. Quantitative and qualitative usefulness of rebamipide in eradication regimen of Helicobacter pylori. Dig Dis Sci. 1958;43(9,suppl.):192S-197S.
Haruma K, Ito M, Kido S, et al. Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci. 2002;47:862-867.
Hiquichi K, Arakawa T, Nebiki H et al. Rebamipide prevents recurrence of gastric ulcers without affecting Helicobacter pylori status. Dig Dis Sci. 1998;43(9,Suppl.):99S-106S.
Tanigawa T, Pai R, Arakawa T, Tarnawski AS. Rebamipide inhibits gastric cancer cell growth. Dig Dis Sci. 2007;52(1):240-247.
Tsukamoto H., Mizoshita T, Katano T, Hayashi N, Ozeki K, Ebi M, Shimura T, Mori Y, Tanida S, Kataoka H, Tsukamoto T, Tatematsu M, Joh T. Preventive effect of rebamipide on N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. Exp Toxicol Pathol. 2015;67(3):271-277. doi:10.1016/j.etp.2015.01.003
Kang DW, Noh YN, Hwang WC, Choi KY, Min do S.Rebamipide attenuates Helicobacter pylori CagA-induced self-renewal capacity via modulation of β-catenin signaling axis in gastric cancer-initiating cells. Biochem Pharmacol. 2016;113:36-44. doi:10.1016/j.bcp.2016.06.003.
Kamada T, Sato M, Tokutomi T, Watanabe T, Murao T, Matsumoto H, Manabe N, Ito M, Tanaka S, Inoue K, Shiotani A, Akiyama T, Hata J, Haruma K. Rebamipide Improves Chronic Inflammation in the Lesser Curvature of the Corpus after Helicobacter pylori Eradication: A Multicenter Study. Biomed Res Int. 2015;2015:865146. doi:10.1155/2015/865146
Almeida R, Silva E, Santos-Silva F, Silberg DG, Wang J, De Bolos C et al. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol. 2003;199:36-40.
Bai YQ, Yamamoto H, Akiyama Y, Tanaka H, Takizawa T, Koike M et al. Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett. 2002;176:47-55.
Bornschein J, Wex T, Peitz U et al. The combined presence of H. pylori infection and gastro-oesophageal reflux disease leads to an up-regulation of CDX2 gene expression in antrum and cardia. J Clin Pathol. 2009;62:254-259.